Scholars Central

PerspectivePublished 15 Feb 2022

Semaglutide Single Dose Pen-Injector

Authors: Mohd Yaser

Mills-Peninsula Medical Center, San Mateo, California, USA

Journal of Obesity and Metabolism

Volume 5 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Subcutaneous semaglutide, delivered by a single-dose pen-injector at a maintenance dose of 2.4mg once weekly, is approved in the USA for weight management in people with a body mass index (BMI) of 30 kg/m2 or higher, or with a BMI of 27 kg/m2 or higher and a minimum of one obesity-related co-morbidity. The semaglutide single-dose pen-injector could be a shield-activated auto-injector. Auto-injectors were at the start developed for emergency use however are used for chronic conditions for many years and for glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment for type 2 diabetes disease (T2D) since 2014. Shield activation entails the discharge of the injection by pushing the pen-injector against the patient's skin, as hostile activation via a button.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Obesity and Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Obesity and Metabolism
  • SubjectDiabetes & Endocrinology
  • SubjectObesity & Weight Management
  • BylineArticles whose byline prints “Mohd Yaser”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels